Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,384
  • Shares Outstanding, K 32,099
  • Annual Sales, $ 57,060 K
  • Annual Income, $ 9,990 K
  • 60-Month Beta 0.55
  • Price/Sales 397.20
  • Price/Cash Flow N/A
  • Price/Book 1.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.14 +8.28%
on 09/21/20
3.57 -4.76%
on 09/29/20
-0.12 (-3.41%)
since 08/28/20
3-Month
2.91 +16.82%
on 07/01/20
3.92 -13.27%
on 07/20/20
+0.36 (+11.84%)
since 06/29/20
52-Week
1.18 +188.14%
on 01/29/20
5.49 -38.07%
on 04/14/20
+1.87 (+122.22%)
since 09/27/19

Most Recent Stories

More News
Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.75, marking a +1.08% move from the previous day.

SMMT : 3.39 (-2.31%)
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?

Is (SMMT) Outperforming Other Medical Stocks This Year?

SMMT : 3.39 (-2.31%)
Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know

Summit Therapeutics PLC (SMMT) closed at $4.20 in the latest trading session, marking a +1.94% move from the prior day.

SMMT : 3.39 (-2.31%)
Summit Therapeutics PLC (SMMT) Stock Moves -0.43%: What You Should Know

In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.

SMMT : 3.39 (-2.31%)
Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?

Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.

MDT : 102.51 (-1.08%)
SMMT : 3.39 (-2.31%)
CGC : 14.45 (+1.69%)
AXGT : 4.90 (+4.70%)
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?

On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.

BLFS : 28.64 (+5.96%)
CYDY : 3.1300 (-3.10%)
SMMT : 3.39 (-2.31%)
AXGT : 4.90 (+4.70%)
Is Summit Therapeutics (SMMT) Outperforming Other Medical Stocks This Year?

Is (SMMT) Outperforming Other Medical Stocks This Year?

SMMT : 3.39 (-2.31%)
Summit Therapeutics PLC (SMMT) Gains As Market Dips: What You Should Know

Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.11, moving +0.33% from the previous trading session.

SMMT : 3.39 (-2.31%)
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?

Is (SMMT) Outperforming Other Medical Stocks This Year?

SMMT : 3.39 (-2.31%)
Summit Therapeutics PLC (SMMT) Gains But Lags Market: What You Should Know

Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.68, moving +0.55% from the previous trading session.

SMMT : 3.39 (-2.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade SMMT with:

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

2nd Resistance Point 3.60
1st Resistance Point 3.53
Last Price 3.39
1st Support Level 3.35
2nd Support Level 3.24

See More

52-Week High 5.49
Fibonacci 61.8% 3.84
Last Price 3.39
Fibonacci 50% 3.33
Fibonacci 38.2% 2.83
52-Week Low 1.18

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar